An oral regimen of
sofosbuvir/ledipasvir plus ribavirin taken for 12 weeks cured most hepatitis C
patients with decompensated cirrhosis, the most advanced stage of liver
disease, according to a presentation on Tuesday at the American Association for the Study of Liver
Diseases (AASLD) Liver Meeting in Boston.
Over years or decades,
chronic hepatitis C virus (HCV)

People with HIV – most of whom had hepatitis B
or C co-infection – generally had good outcomes after liver transplantation due
to hepatocellular carcinoma (HCC), with five-year survival rates similar to
those of HIV-negative transplant recipients and better than those of people who
underwent other types of liver cancer treatment, researchers reported this

Young people who inject drugs (PWID) who undergo opioid
agonist maintenance therapy with methadone or buprenorphine have more than a
60% reduced risk of acquiring hepatitis C virus (HCV) over time
compared to those with no substance use treatment, according to a study presented Monday at the American Association for the Study
of Liver

People who achieve
sustained virological response (SVR) when treated with interferon-based therapy
for hepatitis C have a lower risk of death, are less likely to develop liver
cancer and need fewer liver transplants than those who were treated but not cured,
according to results from a meta-analysis of more than 34,000 patients
presented Sunday at

All but one
participant treated with a co-formulation of sofosbuvir and ledipasvir (Harvoni) achieved sustained virological
response at 12 weeks post-treatment in a study looking at traditionally hard-to-treat
HIV/HCV coinfected patients, researchers reported Sunday at the American Association for the Study
of Liver Diseases (AASLD) Liver Meeting in Boston.
Sofosbuvir/ledipasvir –
a combination nucleotide HCV polymerase

The number of people
using Truvada for pre-exposure
prophylaxis (PrEP) in the US is increasing and a growing proportion of users
are men, according to an analysis of data from approximately half of American
pharmacies presented this week at the HIV Drug Therapy Glasgow conference.
PrEP refers to the use of
antiretroviral medications to prevent HIV

The number of people
using Truvada for pre-exposure
prophylaxis (PrEP) in the US is increasing and a growing proportion of users
are men, according to an analysis of data from approximately half of American
pharmacies presented this week at the HIV Drug Therapy Glasgow conference.
PrEP refers to the use of
antiretroviral medications to prevent HIV

The number of people
using Truvada for pre-exposure
prophylaxis (PrEP) in the US is increasing and a growing proportion of users
are men, according to an analysis of data from approximately half of American
pharmacies presented this week at the HIV Drug Therapy Glasgow conference.
PrEP refers to the use of
antiretroviral medications to prevent HIV

Non-nucleoside
reverse transcriptase inhibitors (NNRTIs) and boosted protease
inhibitors work equally well for people starting HIV treatment for the first
time, with similar viral suppression, CD4 cell gains, and disease
progression, according to a large meta-analysis presented
at IDWeek 2014 earlier this month in Philadelphia. A related study
shed light on factors affecting choice of
initial antiretroviral regimen.

A single-tablet
regimen containing the hepatitis C virus (HCV) nucleotide polymerase
inhibitor sofosbuvir and
the NS5A inhibitor ledipasvir - the combination in Gilead Science’s
recently approved Harvoni pill - was well-tolerated and cured 97% of
patients with HCV genotype 1 in the Phase 3 ION trials, researchers
reported at the IDWeek 2014 meeting earlier this month in
Philadelphia.
The
advent of direct-acting antiviral agents has revolutionized treatment for
chronic hepatitis C, especially with the long-awaited